Denali Therapeutics (DNLI) vs Dyne Therapeutics (DYN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 28.6% versus a gain of 14.5%. Over five years, DYN leads with a +7.3% price change compared with -57.9% for DNLI. Denali Therapeutics is the larger company by market cap ($3.06 billion vs $2.98 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | DYN |
|---|---|---|
| Share price | $19.16 | $15.97 |
| Market cap | $3.06B | $2.98B |
| 1-day change | -0.62% | +3.70% |
| YTD return | +16.05% | -18.35% |
| 1-year return | +28.59% | +14.48% |
| 5-year return | -57.95% | +7.33% |
| EPS (TTM) | $-2.84 | $-3.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.30 | $27.31 |
| 52-week low | $13.75 | $13.73 |
| Distance from 52-week high | -29.82% | -41.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.20% | +125.42% |
| Average volume | 1.61M | 2.77M |
| Shares outstanding | 159.85M | 186.75M |
| Employees | 503 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed DYN by 14.1 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
DNLI vs DYN FAQ
Which is bigger, Denali Therapeutics or Dyne Therapeutics?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $3.06B compared with $2.98B for Dyne Therapeutics (DYN).
Which stock has performed better over the past year, DNLI or DYN?
DNLI returned +28.59% over the past 12 months, compared with +14.48% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Dyne Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics and Biotechnology: Pharmaceutical Preparations for Dyne Therapeutics.